Oxybutynin intravesical - Situs

Drug Profile

Oxybutynin intravesical - Situs

Alternative Names: I-Oxy

Latest Information Update: 30 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Situs Corporation
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 18 Jan 2001 Situs has received 2 US patents for the UROS infusor
  • 01 Sep 2000 Situs has received a US patent for the formulation and delivery of I-OXYTM
  • 02 Aug 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top